LT2363414T - Fviii modifikacija, nukreipta į tam tikrą vietą - Google Patents

Fviii modifikacija, nukreipta į tam tikrą vietą

Info

Publication number
LT2363414T
LT2363414T LTEP11153300.6T LT11153300T LT2363414T LT 2363414 T LT2363414 T LT 2363414T LT 11153300 T LT11153300 T LT 11153300T LT 2363414 T LT2363414 T LT 2363414T
Authority
LT
Lithuania
Prior art keywords
fviii
site
directed modification
modification
directed
Prior art date
Application number
LTEP11153300.6T
Other languages
English (en)
Lithuanian (lt)
Inventor
Clark Q. Pan
John E. Murphy
Baisong Mei
Jonathan S. Strauss
Hendri Tjandra
Jianmin Chen
Thomas Barnett
Liang Tang
Deqian Wamg
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2363414(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of LT2363414T publication Critical patent/LT2363414T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
LTEP11153300.6T 2004-11-12 2005-11-14 Fviii modifikacija, nukreipta į tam tikrą vietą LT2363414T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12

Publications (1)

Publication Number Publication Date
LT2363414T true LT2363414T (lt) 2022-10-25

Family

ID=36337298

Family Applications (5)

Application Number Title Priority Date Filing Date
LTEP11153300.6T LT2363414T (lt) 2004-11-12 2005-11-14 Fviii modifikacija, nukreipta į tam tikrą vietą
LTEP11153297.4T LT2371856T (lt) 2004-11-12 2005-11-14 Fviii modifikacija, nukreipta į tam tikrą vietą
LTEP05849392.5T LT1824988T (lt) 2004-11-12 2005-11-14 Nukreipta į užduotą saitą fviii modifikacija
LTEP16186901.1T LT3130601T (lt) 2004-11-12 2005-11-14 Į vietą nukreipta fviii modifikacija
LTPA2019509C LTC1824988I2 (lt) 2004-11-12 2019-05-09 Nukreipta į užduotą saitą FVII modifikacija

Family Applications After (4)

Application Number Title Priority Date Filing Date
LTEP11153297.4T LT2371856T (lt) 2004-11-12 2005-11-14 Fviii modifikacija, nukreipta į tam tikrą vietą
LTEP05849392.5T LT1824988T (lt) 2004-11-12 2005-11-14 Nukreipta į užduotą saitą fviii modifikacija
LTEP16186901.1T LT3130601T (lt) 2004-11-12 2005-11-14 Į vietą nukreipta fviii modifikacija
LTPA2019509C LTC1824988I2 (lt) 2004-11-12 2019-05-09 Nukreipta į užduotą saitą FVII modifikacija

Country Status (32)

Country Link
US (4) US7632921B2 (cg-RX-API-DMAC7.html)
EP (9) EP3130601B1 (cg-RX-API-DMAC7.html)
JP (5) JP2008524117A (cg-RX-API-DMAC7.html)
KR (7) KR101243564B1 (cg-RX-API-DMAC7.html)
CN (6) CN101124331B (cg-RX-API-DMAC7.html)
AU (1) AU2005304622B2 (cg-RX-API-DMAC7.html)
BE (1) BE2019C523I2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0517795B8 (cg-RX-API-DMAC7.html)
CA (1) CA2586379C (cg-RX-API-DMAC7.html)
CY (3) CY1119292T1 (cg-RX-API-DMAC7.html)
DK (3) DK1824988T3 (cg-RX-API-DMAC7.html)
ES (4) ES2633916T3 (cg-RX-API-DMAC7.html)
FR (1) FR19C1031I2 (cg-RX-API-DMAC7.html)
HN (1) HN2007015683A (cg-RX-API-DMAC7.html)
HR (2) HRP20180481B1 (cg-RX-API-DMAC7.html)
HU (5) HUE033776T2 (cg-RX-API-DMAC7.html)
IL (3) IL182903A (cg-RX-API-DMAC7.html)
LT (5) LT2363414T (cg-RX-API-DMAC7.html)
LU (1) LUC00118I2 (cg-RX-API-DMAC7.html)
MA (1) MA29663B1 (cg-RX-API-DMAC7.html)
MX (3) MX2007005466A (cg-RX-API-DMAC7.html)
NL (1) NL300989I2 (cg-RX-API-DMAC7.html)
NO (3) NO345800B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ555032A (cg-RX-API-DMAC7.html)
PH (2) PH12014500352B1 (cg-RX-API-DMAC7.html)
PL (3) PL2371856T3 (cg-RX-API-DMAC7.html)
PT (4) PT1824988T (cg-RX-API-DMAC7.html)
RU (1) RU2423380C2 (cg-RX-API-DMAC7.html)
SI (4) SI1824988T1 (cg-RX-API-DMAC7.html)
UA (1) UA95225C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006053299A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200703696B (cg-RX-API-DMAC7.html)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
NZ555032A (en) 2004-11-12 2010-02-26 Bayer Healthcare Llc Site-directed modification of FVIII
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CA2653154A1 (en) * 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Prolonged fix analogues and derivatives
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
US9050304B2 (en) 2007-04-03 2015-06-09 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
CA2704234A1 (en) 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
ES2476690T3 (es) * 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
KR101841870B1 (ko) * 2008-05-16 2018-03-23 바이엘 헬스케어 엘엘씨 표적화 응고 인자 및 그의 사용 방법
EP2297330A4 (en) * 2008-06-04 2012-03-14 Bayer Healthcare Llc FVII MUTINES FOR THE TREATMENT OF MORBUS WILLEBRAND
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
US20100099616A1 (en) * 2008-10-17 2010-04-22 Baxter International Inc. Modified blood factors comprising a low degree of water soluble polymer
WO2010062768A1 (en) * 2008-11-03 2010-06-03 Bayer Healthcare Llc Method for the treatment of hemophilia
WO2010060081A1 (en) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
CN102333788A (zh) * 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
US8895281B2 (en) * 2009-03-20 2014-11-25 Hanmi Science Co., Ltd Method for preparing a site-specific physiologically active polypeptide conjugate
CA2756197A1 (en) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
AU2010281453C1 (en) 2009-07-27 2019-08-15 Takeda Pharmaceutical Company Limited Blood coagulation protein conjugates
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN102741422B (zh) * 2009-08-24 2016-06-08 阿穆尼克斯运营公司 凝血因子ⅶ组合物及其制备和使用方法
MX353233B (es) 2009-12-06 2018-01-08 Bioverativ Therapeutics Inc Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CN102770449B (zh) 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
PL2536399T3 (pl) * 2010-02-21 2020-06-29 Bayer Healthcare Llc Sposób aktywacji i sprzęgania biocząsteczek
MX365521B (es) 2010-04-15 2019-06-06 Oligasis Star Polimeros que contienen zwiteriones de alto peso molecular.
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
BR112013011041B1 (pt) * 2010-11-05 2021-05-25 Baxalta GmbH variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica
CA2821945A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
EP2654794B8 (en) 2010-12-22 2020-04-22 Baxalta GmbH Materials and methods for conjugating a water soluble fatty acid derivative to a protein
EP3808378A1 (en) 2011-05-27 2021-04-21 Baxalta GmbH Therapeutic proteins with increased half-life and methods of preparing same
HUE043894T2 (hu) 2011-06-10 2019-09-30 Bioverativ Therapeutics Inc Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
JP2014522838A (ja) 2011-07-08 2014-09-08 バイオジェン アイデック ヘモフィリア インコーポレイテッド 第ｖｉｉｉ因子キメラおよびハイブリッドポリペプチドならびにその使用法
CA2849673A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
EP2814840B1 (en) 2012-02-15 2019-11-13 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
LT2968477T (lt) 2013-03-15 2020-03-10 Bioverativ Therapeutics Inc. Faktoriaus viii polipeptido kompozicijos
WO2014150477A1 (en) * 2013-03-15 2014-09-25 Bayer Healthcare Llc Recombinant factor viii formulations
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
EP3033098B1 (en) 2013-08-14 2022-06-22 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT3041513T (lt) 2013-09-08 2020-11-25 Kodiak Sciences Inc. Viii faktoriaus cviterioninių polimerų konjugatai
KR20160090810A (ko) * 2013-10-22 2016-08-01 디비브이 테크놀로지스 (소시에떼 아노님) 혈액 인자에 대한 관용 유도에 의한 혈우병의 치료 방법
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
EP3082848B1 (en) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
CN106414491B (zh) * 2014-01-20 2021-06-18 奥克塔法马股份有限公司 一种制备FVIII:C/FVIII:Ag比例提高的因子VIII的方法
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
KR102385372B1 (ko) 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
WO2015154090A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
SG11201608390SA (en) 2014-04-10 2016-11-29 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
JP6676551B2 (ja) 2014-07-02 2020-04-08 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォンウィルブランド因子
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
AU2016231327B2 (en) 2015-03-06 2018-08-09 CSL Behring Lengnau AG Modified von Willebrand factor having improved half-life
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
AU2017205776B2 (en) 2016-01-07 2020-09-10 CSL Behring Lengnau AG Mutated von Willebrand factor
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
JP7235511B2 (ja) * 2016-06-24 2023-03-08 モガム・インスティテュート・フォー・バイオメディカル・リサーチ 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート
SG10201912360SA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
DK3538134T3 (da) 2016-11-11 2022-02-07 CSL Behring Lengnau AG Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse
CN110177804A (zh) 2016-11-16 2019-08-27 拜尔健康护理有限责任公司 红细胞靶向的因子viii及使用其的方法
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
KR20190091292A (ko) 2016-12-02 2019-08-05 바이오버라티브 테라퓨틱스 인크. 응고 인자에 대한 면역 내성 유도 방법
TW201831521A (zh) 2017-01-31 2018-09-01 美商生物化學醫療公司 因子ｉｘ融合蛋白以及其製備方法及使用方法
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
US12440572B2 (en) 2018-05-18 2025-10-14 Zhengzhou Gensciences Inc. FVIII fusion protein and use thereof
CA3099049A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
EP4069269A4 (en) * 2019-12-06 2023-12-27 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
NZ256921A (en) 1992-10-02 1996-05-28 Pharmacia Ab Formulations of coagulation factor viii and a non-ionic surfactant and their preparation
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
JPH09504174A (ja) 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
WO1996041813A2 (en) 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
AU691111B2 (en) * 1995-06-21 1998-05-07 Google Technology Holdings LLC Method and antenna for providing an omnidirectional pattern
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
KR20000029673A (ko) * 1996-08-02 2000-05-25 오르토-맥네일 파마슈티칼, 인코퍼레이티드 단일의공유결합된ｎ-말단수용성폴리머를갖는폴리펩티드
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
CA2296770A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2306629A1 (en) * 1997-10-17 1999-04-29 Harvest Technologies Corporation Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
ES2233036T3 (es) 1998-04-27 2005-06-01 Opperbas Holding B.V. Composicion farmaceutica que comprende factor viii y liposomas neutros.
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
ES2292255T5 (es) 1998-11-10 2017-05-19 Stichting Sanquin Bloedvoorziening Polipéptido del factor 8 con actividad de factor 8:C
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
KR100731826B1 (ko) 1999-01-14 2007-06-22 볼더 바이오테크놀로지 인코퍼레이티드 유리 시스테인 잔기를 함유하는 단백질의 제조 방법
AU5282200A (en) 1999-05-24 2000-12-12 American National Red Cross, The Methods of reducing factor viii clearance and compositions therefor
RU2278123C2 (ru) * 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
CA2422902A1 (en) 2000-09-19 2002-03-28 Emory University Modified factor viii
CA2434097A1 (en) 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
WO2002077218A1 (en) * 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
AU2002312660A1 (en) 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
EP2110385A1 (en) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
DE60230456D1 (de) 2001-10-05 2009-01-29 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
AU2003232482A1 (en) 2002-04-18 2003-10-27 Merck Patent Gmbh Modified factor viii
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
JP4490369B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション マレアミド酸ポリマー誘導体及びこれらの生物学的複合体
US7910661B2 (en) 2003-01-06 2011-03-22 Nektar Therapeutics Thiol-selective water-soluble polymer derivatives
DK1596887T3 (da) 2003-02-26 2022-06-20 Nektar Therapeutics Polymer-Faktor VIII-konjugat
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
AU2004238869B2 (en) * 2003-05-12 2009-06-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
KR101128320B1 (ko) 2003-05-23 2012-04-12 넥타르 테라퓨틱스 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
DE602004026474D1 (de) 2003-12-03 2010-05-20 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
NZ555032A (en) 2004-11-12 2010-02-26 Bayer Healthcare Llc Site-directed modification of FVIII
WO2006103298A2 (en) 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Blood coagulation fviii analogues
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ

Also Published As

Publication number Publication date
HK1117875A1 (en) 2009-01-23
US20100081615A1 (en) 2010-04-01
CN107082806A (zh) 2017-08-22
PH12014500352B1 (en) 2019-09-25
US9096656B2 (en) 2015-08-04
LT2371856T (lt) 2022-08-25
PH12014500352A1 (en) 2015-07-20
LT1824988T (lt) 2017-10-25
EP3323829B1 (en) 2020-07-15
RU2007121517A (ru) 2008-12-20
BR122016022033B1 (pt) 2021-03-02
KR20180110192A (ko) 2018-10-08
PT3130601T (pt) 2020-10-01
KR20070110260A (ko) 2007-11-16
CN101124331A (zh) 2008-02-13
IL234433B (en) 2019-11-28
EP2363414A3 (en) 2012-03-21
DK2363414T3 (da) 2022-08-08
HK1182121A1 (en) 2013-11-22
CY1119292T1 (el) 2018-02-14
CA2586379A1 (en) 2006-05-18
US20160051633A1 (en) 2016-02-25
EP1824988A4 (en) 2008-12-31
ES2930143T3 (es) 2022-12-07
CY2019024I2 (el) 2019-11-27
KR20130036780A (ko) 2013-04-12
KR101483917B1 (ko) 2015-01-16
HUE050542T2 (hu) 2020-12-28
JP2015134780A (ja) 2015-07-27
ZA200703696B (en) 2008-08-27
CN105148287A (zh) 2015-12-16
LT3130601T (lt) 2020-09-10
CA2586379C (en) 2012-04-03
LTC1824988I2 (lt) 2021-02-25
HUS1900026I1 (hu) 2022-04-28
KR20140019489A (ko) 2014-02-14
NL300989I2 (nl) 2019-11-28
HRP20070268A2 (en) 2007-09-30
SI2371856T1 (sl) 2022-09-30
CN105753968A (zh) 2016-07-13
JP2013067621A (ja) 2013-04-18
JP6559642B2 (ja) 2019-08-14
EP2772500B1 (en) 2019-12-25
EP1824988A2 (en) 2007-08-29
US20130274445A1 (en) 2013-10-17
CN101124331B (zh) 2013-04-24
KR101468345B1 (ko) 2014-12-03
CY2019024I1 (el) 2019-11-27
CY1123384T1 (el) 2021-12-31
LUC00118I1 (cg-RX-API-DMAC7.html) 2019-05-13
IL232540A0 (en) 2014-06-30
PT2363414T (pt) 2022-08-04
KR101243564B1 (ko) 2013-03-27
BR122016022033B8 (pt) 2021-05-25
HUE059193T2 (hu) 2022-10-28
CN103214569B (zh) 2016-12-28
NO20200044A1 (no) 2007-06-27
LUC00118I2 (cg-RX-API-DMAC7.html) 2019-12-27
JP2017101028A (ja) 2017-06-08
IL182903A0 (en) 2007-08-19
EP2772500A1 (en) 2014-09-03
EP3243834A1 (en) 2017-11-15
FR19C1031I2 (fr) 2020-06-05
PL2363414T3 (pl) 2022-09-05
DK2371856T3 (en) 2022-08-08
EP2371856B1 (en) 2022-05-18
EP2363414B1 (en) 2022-05-18
EP2371856A2 (en) 2011-10-05
CN103102406B (zh) 2015-05-27
MA29663B1 (fr) 2008-08-01
EP3130601B1 (en) 2020-07-15
EP3243833B1 (en) 2020-06-17
WO2006053299A3 (en) 2006-08-24
PL1824988T3 (pl) 2018-01-31
PL2371856T3 (pl) 2022-08-22
JP6487895B2 (ja) 2019-03-20
NO345800B1 (no) 2021-08-09
BRPI0517795A8 (pt) 2018-12-26
HN2007015683A (es) 2011-07-11
BRPI0517795B1 (pt) 2020-03-31
KR101904630B1 (ko) 2018-10-04
MX350293B (es) 2017-09-04
CN103214569A (zh) 2013-07-24
HUE060016T2 (hu) 2023-01-28
SI3130601T1 (sl) 2020-11-30
EP2371856A3 (en) 2012-03-14
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
BRPI0517795A (pt) 2008-10-21
DK1824988T3 (en) 2017-08-07
NO20072997L (no) 2007-06-27
US20060115876A1 (en) 2006-06-01
ES2633916T3 (es) 2017-09-26
US7632921B2 (en) 2009-12-15
KR101654011B1 (ko) 2016-09-05
SI1824988T1 (sl) 2017-11-30
HRP20180481B1 (hr) 2022-02-18
MX2007005466A (es) 2007-10-19
UA95225C2 (ru) 2011-07-25
HUE033776T2 (en) 2018-01-29
EP1824988B1 (en) 2017-04-19
NZ555032A (en) 2010-02-26
ES2930159T3 (es) 2022-12-07
HRP20070268B1 (hr) 2018-04-20
NO344606B1 (no) 2020-02-10
KR20160105928A (ko) 2016-09-07
US9364520B2 (en) 2016-06-14
AU2005304622A1 (en) 2006-05-18
BRPI0517795B8 (pt) 2021-05-25
PT2371856T (pt) 2022-08-12
WO2006053299A2 (en) 2006-05-18
JP6109523B2 (ja) 2017-04-05
JP6018238B2 (ja) 2016-11-02
AU2005304622B2 (en) 2012-03-29
LTPA2019509I1 (lt) 2019-08-26
MX392760B (es) 2025-03-24
CN103102406A (zh) 2013-05-15
IL182903A (en) 2014-09-30
JP2008524117A (ja) 2008-07-10
FR19C1031I1 (cg-RX-API-DMAC7.html) 2019-06-28
BE2019C523I2 (cg-RX-API-DMAC7.html) 2025-02-10
ES2821832T3 (es) 2021-04-27
EP3323829A1 (en) 2018-05-23
EP3243833A1 (en) 2017-11-15
JP2017105773A (ja) 2017-06-15
HK1218718A1 (zh) 2017-03-10
IL232540A (en) 2017-08-31
EP3153181A1 (en) 2017-04-12
EP3130601A1 (en) 2017-02-15
EP2363414A2 (en) 2011-09-07
NL300989I1 (nl) 2019-05-22
KR20120136413A (ko) 2012-12-18
CN105148287B (zh) 2019-07-09
HRP20180481A2 (hr) 2018-06-29
PH12019501613A1 (en) 2020-09-14
KR20140091618A (ko) 2014-07-21
RU2423380C2 (ru) 2011-07-10
PT1824988T (pt) 2017-07-21

Similar Documents

Publication Publication Date Title
IL234433B (en) Site-directed modification of factor viii
GB0426503D0 (en) Improved osteotome
IL183634A0 (en) Polymer-von willebrand factor-conjugates
EP1802588A4 (en) SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
EP1773871A4 (en) COMPOUNDS ASSOCIATED WITH TISSUE DIFFERENTIATION FACTOR AND THEIR ANALOGUES
EP1785131A4 (en) EXTERNAL PREPARATION OF TYPE S / O
ZA200606315B (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
AU300055S (en) Scrubber
PL1720633T3 (pl) Płuczka wieżowa gazu
GB0428026D0 (en) Infant aid
GB0418912D0 (en) Improved building components
GB2416051B (en) Selection of component
ZA200508325B (en) Manufacture of kerbstones
GB0421155D0 (en) Piece of mind plan
GB0415217D0 (en) Compounds and uses thereof
GB0412872D0 (en) Novel structures
PL369353A1 (pl) Zestaw elementów budowlanych
AU157294S (en) External cornice corner member
TWM275831U (en) Improved structure of cinerary urn
SI1835938T1 (sl) Konjugati polimera in von Willebrandovega faktorja
GB0415721D0 (en) Novel preparation
GB0402464D0 (en) Child walker